E-ISSN 0976-2779 | ISSN 0975-8453
 

Review Article 


Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review

Carcinoma: A Mini Review Hendrian D. Soebagjo.

Abstract
Basal cell carcinoma (BCC) is the most common cancer in the world. This study aims to review vismodegib treatment in BCC patients. Vismodegib has been approved for the treatment of adults with mBCC, or with laBCC that has recurred after surgery or who are not eligible for surgical procedure nor radiation. Despite all advantages it possesses, this drug still has limitations such as its inevitably occurring side effects of Vismodegib which lead to a significant rate of treatment discontinuation limiting complete drug exposure as described in previous studies. Hence, long-term continuous treatment with Vismodegib might be not feasible for certain group of patients. Vismodegib had become an established treatment option for patients with locally advanced or metastatic BCC in clinical practice.

Key words: vismodegib, basal cell carcinoma, treatment


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Carcinoma: A Mini Review Hendrian D. Soebagjo
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Carcinoma: A Mini Review Hendrian D. Soebagjo. Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review. SRP. 2020; 11(3): 587-595. doi:10.31838/srp.2020.3.77


Web Style

Carcinoma: A Mini Review Hendrian D. Soebagjo. Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review. http://www.sysrevpharm.org//?mno=96004 [Access: May 31, 2020]. doi:10.31838/srp.2020.3.77


AMA (American Medical Association) Style

Carcinoma: A Mini Review Hendrian D. Soebagjo. Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review. SRP. 2020; 11(3): 587-595. doi:10.31838/srp.2020.3.77



Vancouver/ICMJE Style

Carcinoma: A Mini Review Hendrian D. Soebagjo. Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review. SRP. (2020), [cited May 31, 2020]; 11(3): 587-595. doi:10.31838/srp.2020.3.77



Harvard Style

Carcinoma: A Mini Review Hendrian D. Soebagjo (2020) Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review. SRP, 11 (3), 587-595. doi:10.31838/srp.2020.3.77



Turabian Style

Carcinoma: A Mini Review Hendrian D. Soebagjo. 2020. Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review. Systematic Reviews in Pharmacy, 11 (3), 587-595. doi:10.31838/srp.2020.3.77



Chicago Style

Carcinoma: A Mini Review Hendrian D. Soebagjo. "Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review." Systematic Reviews in Pharmacy 11 (2020), 587-595. doi:10.31838/srp.2020.3.77



MLA (The Modern Language Association) Style

Carcinoma: A Mini Review Hendrian D. Soebagjo. "Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review." Systematic Reviews in Pharmacy 11.3 (2020), 587-595. Print. doi:10.31838/srp.2020.3.77



APA (American Psychological Association) Style

Carcinoma: A Mini Review Hendrian D. Soebagjo (2020) Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review. Systematic Reviews in Pharmacy, 11 (3), 587-595. doi:10.31838/srp.2020.3.77